Meningococcal Vaccine MarketThe global meningococcal vaccine market is experiencing significant growth, driven by rising ...

The story has been updated to correct the FDA approval date to Friday, February 14 On Friday, February 14, the FDA approved ...

For patients transitioning from rituximab to ravulizumab, meningococcal vaccination can be safely done within 6 months after stopping rituximab.

Jaxon Knowles' family is raising money in honor of their "miracle baby," as his mom says his Feb. 17 death "still doesn't ...

The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against ...

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).

(HealthDay News) — The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive meningococcal disease (IMD), ...

The FDA approved GSK's Penmenvy vaccine for ages 10-25, targeting five major meningococcal serogroups: A, B, C, W, and Y. Phase 3 trials with 4,800 participants showed the vaccine has a safety ...

Tony Wood, Chief Scientific Officer, GSK, said: "We are excited about the opportunities ahead to help improve meningococcal vaccination coverage in the United States, especially for IMD caused by ...

GSK (GSK) plc announced that the Food and Drug Administration has approved Penmenvy for use in individuals aged 10 through 25 years. The ...

The approvals come as Robert F. Kennedy Jr.—who has been critical of vaccines—takes leadership of the Department of Health ...